PPD Development LP
PPD Development LP is a global contract research organization (CRO) that provides comprehensive clinical trial and research support services to federal government agencies. As a subsidiary of Thermo Fisher Scientific, PPD offers expertise in areas such as regulatory affairs, clinical site monitoring, data management, and analytical testing to support the development of vaccines, therapeutics, diagnostics, and medical countermeasures. The company has been registered to receive federal awards since 2003 and has established itself as a key partner in advancing public health initiatives and medical research programs across multiple agencies and therapeutic areas.
Through prime federal contract awards, PPD Development LP has provided a wide range of services to agencies such as the National Institutes of Health (NIH), Department of Defense (DoD), and Department of Health and Human Services (HHS). These services include clinical site monitoring for the National Institute of Allergy and Infectious Diseases (NIAID), regulatory management support for NIAID's Regulatory Management Center, and comprehensive clinical trial management for COVID-19 studies. PPD has also conducted exploratory analyses for the National Human Genome Research Institute, developed U.S. Army blood products concepts of operations, and provided expanded access treatment protocols for HHS during the COVID-19 pandemic. The company has received multiple high-value contracts, including a $222 million contract from HHS for a Phase 2 clinical trial on acute respiratory distress syndrome and a $186 million contract from NIAID for clinical site monitoring services. Additionally, PPD has provided subcontract services to prime contractors such as General Dynamics Information Technology for various DoD and civilian agency projects.
PPD Development LP's involvement in federal grant awards primarily consists of subcontract work supporting prime grantees. The company has provided services for projects such as the DMPA XT study and Sayana Press initiatives through Family Health International, as well as clinical trial support for HIV-to-HIV deceased donor kidney transplantation research at Johns Hopkins University. PPD has also assisted the University of Pittsburgh with site responsibilities for pediatric clinical studies, including participant recruitment, data collection, and adverse event reporting. These grant-funded projects demonstrate PPD's capabilities in managing complex clinical trials, handling specialized laboratory services, and supporting research in various therapeutic areas.
The company holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies. Notable among these is a $545 million contract with NIAID for comprehensive and rapid response capabilities in research programs, supporting a range of clinical and non-clinical services. PPD also holds a $346 million multiple-award contract for NIAID's Early Phase Clinical Trial Units program, facilitating Phase 0 through Phase II trials for infectious diseases. Other IDVs include a $49.9 million contract with the National Institute on Drug Abuse for Blueprint MedTech clinical studies, a $24 million contract for regulatory affairs support in the same program, and a $548 million multiple-award contract with the National Cancer Institute for cancer trials support. These IDVs position PPD Development LP to provide a wide array of services across multiple agencies, including clinical trial management, regulatory affairs support, and specialized research and development activities.
ZANENSW6C665 541714
Not listed PPD Building, 929 N Front St, Wilmington, NC 28401, USA
5/6/03 1/6/26 Allucent Government Services (Us) LLC
Allucent Government Services (Us) LLC, formerly known as Pharm-Olam, LLC, is a for-profit clinical research organization specializing in comprehensive services to support clinical trials and medical countermeasure development for the U.S. federal government. The company offers expertise across the entire clinical trial lifecycle, from preclinical studies through late-stage trials, with a focus on infectious diseases research, public health preparedness, and regulatory support for biopharmaceutical product development. Allucent's core capabilities include clinical trial planning and execution, subject matter expert consultation, specimen collection and management, and support for the development of medical countermeasures against chemical, biological, radiological, nuclear, pandemic influenza, and emerging infectious disease threats.
Allucent has been awarded numerous prime contracts and task orders from various federal agencies, primarily within the Department of Health and Human Services (HHS) and the Department of Defense (DoD). For HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR), Allucent has provided clinical trial planning and execution services, subject matter expert consultation, and specimen collection support under a $400 million indefinite delivery contract. Specific task orders have included a $343.2 million award for clinical trial planning and execution, a $34.1 million award for specimen collection services, and smaller awards for clinical studies network support. The company has also received contracts from the National Institutes of Health (NIH) for subject matter expert consulting on drug metabolism pharmacokinetics and to support infectious disease clinical trials under the Early Phase Clinical Trial Units program. Additionally, Allucent was awarded two other transaction agreements from the Army, totaling nearly $89 million, for prototype clinical trials involving COVID-19 treatments and military facility trials. These contracts have primarily been performed at Allucent's division in Houston, Texas, and have not been associated with any set-aside designations.
Allucent holds three significant federal contract Indefinite Delivery Vehicles (IDVs). The first is a $30 million single-award IDV from NIH's National Institute of Allergy and Infectious Diseases for preclinical services supporting biopharmaceutical product development, including planning, assay development, manufacturing, and regulatory activities. The second is a $346.6 million multiple-award IDV under the Early Phase Clinical Trial Units program to conduct Phase 0-III clinical trials for infectious disease products. The third and largest is a $550 million single-award IDV from ASPR for clinical trial planning and execution services, which serves as the vehicle for multiple delivery orders supporting ASPR's medical countermeasure programs. These IDVs collectively demonstrate Allucent's comprehensive capabilities in supporting the development of medical countermeasures for various threats, as well as its ability to efficiently conduct domestic and international clinical trials for various investigational products. Task orders under these IDVs have been awarded by agencies such as NIAID and ASPR, further solidifying Allucent's role as a key partner in federal efforts to advance medical research and preparedness.
C7DJDL6EZT94 541715
Not listed 2000 Centregreen Way #300, Cary, NC 27513, USA
8/10/20 4/22/25 Icon Government And Public Health Solutions, Inc.
Icon Government And Public Health Solutions, Inc. is a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, specializing in clinical research and offering end-to-end services from compound selection to Phase I-IV clinical trials. It is a foreign-owned, for-profit organization, registered in the System for Award Management (SAM) since 2001.
Icon Government And Public Health Solutions, Inc. has been awarded numerous prime and subcontracts by federal agencies, primarily the Department of Health and Human Services (HHS), Department of Defense (DoD), and National Institutes of Health (NIH). The majority of its contracts involve providing comprehensive clinical trial planning and execution services for medical countermeasures like vaccines, therapeutics, and other products against infectious diseases, chemical/biological threats, and public health emergencies like COVID-19. This includes activities such as protocol development, site selection, regulatory submissions, participant recruitment, data management, quality assurance, and reporting. Icon leverages its network of research sites and team of clinical research associates, scientists, nurses, and project managers to conduct domestic and international trials across all phases. In addition to HHS and DoD, Icon has supported clinical research programs for agencies like the Defense Health Agency and U.S. Army Medical Command. While most awards utilize no set-asides, Icon has participated in socioeconomic set-asides on certain subcontracts.
Icon Government And Public Health Solutions, Inc. holds several prominent indefinite delivery vehicles focused on clinical trials and research support. These include a $400 million Clinical Trials Planning and Execution IDIQ from HHS's Office of the Assistant Secretary for Preparedness and Response enabling rapid task order issuance for medical countermeasure studies, a $545 million Comprehensive and Rapid Response to NIAID Research Programs IDIQ to support the full range of basic research to clinical trials for the NIH's National Institute of Allergy and Infectious Diseases, and a $346 million Early Phase Clinical Trial Units IDIQ providing domestic and international Phase 0 to Phase II trials of investigational infectious disease products for NIAID. Icon was also awarded a $6 million Federal Supply Schedule contract allowing streamlined procurement of professional scientific and technical services across over 70 labor categories. Clients can acquire clinical trial, regulatory, data management, manufacturing, and other services mapped to hourly labor rates under the GSA schedule.
JHJ7HXD5XR47 541715
Not listed 731 Arbor Way #100, Blue Bell, PA 19422, USA
9/27/01 8/28/25 Dynport Vaccine Company LLC
Dynport Vaccine Company LLC DVC Segment Division is a subsidiary of General Dynamics Corp. that provides a range of research, development, manufacturing, and testing services to support biopharmaceutical products targeting infectious diseases.
Through past federal contracts, Dynport has provided preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and cGMP production services in support of therapeutics and vaccines for emerging infectious diseases. Major customers include NIH, HHS, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Prime contract awards have funded process development, assay validation, pilot manufacturing, Phase I trials, and stability testing of vaccine candidates over 1-5 year periods. Subcontracts have supported clinical trials and CGMP cell bank production. Most awards utilize firm fixed price or cost plus fixed fee structures without set asides. Places of performance are centered at Dynport's Maryland-based locations.
Dynport holds several infectious disease-focused IDVs as a prime contractor, most notably the $30 million Preclinical Services for Biopharmaceutical Product Development contract from NIH-NIAID. This single-award IDIQ covers process development, assay validation, CGMP production, and regulatory documentation to support candidate vaccines and therapies from early inception through preclinical advancement. Dynport also holds the $36 million Diagnostic Pre-Clinical Services Program contract, which funds development processes needed to bring candidate infectious disease diagnostics to market. Additionally, Dynport is one of multiple awardees under the $346 million Early Phase Clinical Trial Units IDIQ, which has funded Phase I trial services under cost plus fixed fee delivery orders to date.
LXNEGTYDR755 541714
Not listed 110 Thomas Johnson Dr, Frederick, MD 21702, USA
4/2/02 12/4/25 Duke University
Duke University is a top-ranked global institution dedicated to expanding the frontiers of knowledge and applying it in service to society. The university is home to about 13,000 undergraduate and graduate students and has a world-class faculty. Duke University's Office of Research Administration Division oversees and provides administrative support for the university's sponsored research and educational grants and contracts from the federal government and other sponsors. Through federal contract and grant awards, Duke University provides a diverse array of goods and services to various government agencies, including clinical research, biomedical studies, educational services, and advanced technological development.
Duke University has been awarded numerous federal contracts to provide a wide range of goods and services. As a prime contractor for the Centers for Disease Control and Prevention (CDC), Duke has conducted clinical research and immunization safety assessment services under an indefinite delivery indefinite quantity (IDIQ) vehicle. The university has also provided executive training services to the Federal Emergency Management Agency (FEMA). Duke has delivered brain research, educational services, and infrastructure support through awards from agencies like the Department of Veterans Affairs (VA), Defense Advanced Research Projects Agency (DARPA), National Aeronautics and Space Administration (NASA), and Department of the Navy. Many of Duke's contract awards have been set-aside free, without any specific socioeconomic designations. The university has collaborated with various partners on both prime and subcontracts to deliver these services.
Duke University has been awarded numerous federal grants to conduct critical research across various disciplines. These grants have enabled Duke to provide services spanning biomedical research, brain and neuroscience studies, cancer research, cardiovascular disease research, gene therapy development, climate and environmental science, behavioral and social science research, and many other areas. Key federal grant programs supporting Duke's research include extramural programs from the National Institutes of Health (NIH) institutes and centers, as well as programs from the National Science Foundation (NSF), Department of Defense agencies like the Defense Health Agency, and other federal research agencies. Duke has frequently collaborated with other universities, research institutions, and industry partners as either a prime or sub-awardee on these grants, contributing to groundbreaking research and scientific advancements.
The Defense Advanced Research Projects Agency (DARPA) awarded Duke University an Other Transaction (OT) indefinite delivery vehicle (IDV) contract called MEASQUIT, valued at $1,000,000, to provide research and development services related to measurement-based quantum information and transduction. No set-aside designations were used for this IDV award to Duke's Office of Research Administration Division, which serves as the prime contractor. The full scope of services Duke will provide under this IDV is not specified, but it aligns with Duke's expertise across various research domains applicable to government agencies. This IDV demonstrates Duke's capability to engage in cutting-edge research and development projects that have potential applications in advanced technologies for defense and national security purposes.
TP7EK8DZV6N5 611310
Not listed 2200 W Main St, Durham, NC 27705, USA
2/26/02 9/28/25